Top Markets
#1 Akedo Akedo +84.18%
#2 TENDIES TENDIES +73.28%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.58%
#5 Mubarak Mubarak +31.80%
#6 MultiversX MultiversX +27.43%
#7 Bitway Bitway +26.80%
#8 Cash Cat Cash Cat +24.01%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Clasificación en acciones #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Precio por acción
$8.16
Última sincronización: 2025-06-26
Capitalización bursátil
$234.57M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Regulus Therapeutics Inc. (RGLS)

Categoría

Healthcare
Ingresos de Regulus Therapeutics Inc. (RGLS)
Ingresos en Mar 2025 TTM: $340.00K
Según los últimos informes financieros de Regulus Therapeutics Inc., los ingresos actuales de la empresa (TTM) son $340.00K. En 2023, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2022, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Regulus Therapeutics Inc. desde 2010 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 3,712,929.41%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,770,866.86%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 655,194.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 4,630,584.45%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH